171 related articles for article (PubMed ID: 35123028)
1. Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.
Xie H; Wen X; Li J; Chen W; Chen M; Zhang L; Lv M; Zhou S; Bai S; Zhao W; Wang J; Wu J
Int J Infect Dis; 2022 Apr; 117():97-102. PubMed ID: 35123028
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of the neutralizing activity against SARS-CoV-2 Wuhan-Hu-1 strain and variants of concern: Performance evaluation of a pseudovirus-based neutralization assay.
D'Apice L; Trovato M; Gramigna G; Colavita F; Francalancia M; Matusali G; Meschi S; Lapa D; Bettini A; Mizzoni K; Aurisicchio L; Di Caro A; Castilletti C; De Berardinis P
Front Immunol; 2022; 13():981693. PubMed ID: 36225911
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China.
Zhang H; Hua Q; Nani Xu N; Zhang X; Chen B; Ma X; Hu J; Chen Z; Yu P; Lei H; Wang S; Ding L; Fu J; Liao Y; Yang J; Jiang J; Lv H
Elife; 2023 Mar; 12():. PubMed ID: 36928099
[TBL] [Abstract][Full Text] [Related]
4. Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice.
Song S; Zhou B; Cheng L; Liu W; Fan Q; Ge X; Peng H; Fu YX; Ju B; Zhang Z
Virol J; 2022 Jan; 19(1):2. PubMed ID: 34983583
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
Huang T; Hu Q; Zhou X; Yang H; Xia W; Cao F; Deng M; Teng X; Ding F; Zhong Z; Gao L; Sun J; Gong L
BMC Infect Dis; 2024 Apr; 24(1):413. PubMed ID: 38641791
[TBL] [Abstract][Full Text] [Related]
6. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization.
Cheng ZJ; Huang H; Zheng P; Xue M; Ma J; Zhan Z; Gan H; Zeng Y; Lin R; Li S; Zhong R; Li S; Wang H; Sun B
Allergy; 2022 Aug; 77(8):2404-2414. PubMed ID: 35255171
[TBL] [Abstract][Full Text] [Related]
9. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
[TBL] [Abstract][Full Text] [Related]
10. Generation of neutralizing antibodies against Omicron, Gamma and Delta SARS-CoV-2 variants following CoronaVac vaccination.
Silva ARD; Villas-Boas LS; Tozetto-Mendoza TR; Honorato L; Paula A; Witkin SS; Mendes-Correa MC
Rev Inst Med Trop Sao Paulo; 2022; 64():e19. PubMed ID: 35239863
[TBL] [Abstract][Full Text] [Related]
11. Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study.
Li J; Xie H; Chen W; Chen M; Bai S; Zhao W; Zhou T; Gao P; Zhang L; Wang Q; Pang X; Huang C; Wu J
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298542
[TBL] [Abstract][Full Text] [Related]
12. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
[TBL] [Abstract][Full Text] [Related]
13. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
14. [Immunogenicity, safety and immune persistence of the sequential booster with the recombinant protein-based COVID-19 vaccine (CHO cell) in healthy people aged 18-84 years].
Yao DY; Chen YP; Ding F; Hu XS; Liang ZZ; Xing B; Cao YF; Zhang TQ; Wang XL; Liao YT; Yang J; Lyu HK
Zhonghua Yu Fang Yi Xue Za Zhi; 2024 Jan; 58(1):25-32. PubMed ID: 38228546
[No Abstract] [Full Text] [Related]
15. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Chalkias S; Eder F; Essink B; Khetan S; Nestorova B; Feng J; Chen X; Chang Y; Zhou H; Montefiori D; Edwards DK; Girard B; Pajon R; Dutko FJ; Leav B; Walsh SR; Baden LR; Miller JM; Das R
Nat Med; 2022 Nov; 28(11):2388-2397. PubMed ID: 36202997
[TBL] [Abstract][Full Text] [Related]
17. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
Chalkias S; Schwartz H; Nestorova B; Feng J; Chang Y; Zhou H; Dutko FJ; Edwards DK; Montefiori D; Pajon R; Leav B; Miller JM; Das R
medRxiv; 2022 Mar; ():. PubMed ID: 35291289
[TBL] [Abstract][Full Text] [Related]
18. [Immunogenicity and safety of a booster vaccination with an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in adults aged 18 to 59 years].
Pan HX; Huang BY; Deng Y; Chu K; Hu JL; Zhu DD; Wu JL; Zhang L; Wang M; Huang WJ; Tan WJ
Zhonghua Yi Xue Za Zhi; 2022 Jan; 102(4):279-285. PubMed ID: 35073677
[No Abstract] [Full Text] [Related]
19. Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer.
Naranbhai V; St Denis KJ; Lam EC; Ofoman O; Garcia-Beltran WF; Mairena CB; Bhan AK; Gainor JF; Balazs AB; Iafrate AJ;
Cancer Cell; 2022 Jan; 40(1):103-108.e2. PubMed ID: 34990570
[TBL] [Abstract][Full Text] [Related]
20. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
